Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
PAT after MI is Rs. 41 crore which is 162% increase
PAT after MI is Rs. 41 crore which is 162% increase
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
This certification will open new markets for the Kwality Pharma
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Mesalazine is used to treat inflammatory bowel disease
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Subscribe To Our Newsletter & Stay Updated